Back to FMC
FMC Stock: Earnings, Debt and Dividend Risks
$FMCBEARISHAgricultural Inputs

FMC Stock: Earnings, Debt and Dividend Risks

FMC closed Friday, November 13, at $5.21 after a steep decline over the past year. The analyst consensus is Hold, but a large quarterly earnings miss, negative trailing EPS, heavy debt and a high dividend yield leave key questions about financial stability and the path to recovery.

November 14, 202612 min read
Current Price
$5.21
+2.96%
Analyst Rating
Hold
Price Target
$10.86
108.4% upside
P/E Ratio
-0.16

Executive Summary

Investment Thesis: FMC is a global crop-protection company whose shares have fallen sharply, while the latest reported quarter showed a substantial EPS miss and financial data indicate negative trailing earnings and significant debt. Analyst price targets imply potential upside from the Friday, November 13 close, but estimates vary materially across supplied sources and do not resolve concerns about earnings, cash generation or the dividend. The central question is whether operating performance can stabilize before balance-sheet and payout pressures intensify.

Current Price: $5.21 as of Friday, November 13 | Key Metric: EPS (TTM) of -$32.00 in supplied company data | Stance: BEARISH

US stock markets are closed on Saturday, November 14. The next regular trading session is Monday, November 16. The supplied price data show FMC up $0.15, or 2.96%, from the previous close of $5.06 on Friday. A separate market-data excerpt reports a different percentage change, so investors should verify the precise close and return against their brokerage or a current market-data source.

Company Overview

FMC Corporation develops and sells agricultural chemicals that help growers protect crops from insects, weeds and diseases. Its business depends on farmers’ crop economics, seasonal application patterns, product registrations and the company’s ability to bring differentiated products to market.

Key Products & Competitive Position

  • Core Business: Crop-protection products for commercial agriculture, including insecticides, herbicides and fungicides.
  • Key Products: Branded chemical solutions and developing biological crop-protection products. Product availability and permitted uses vary by country and registration.
  • Competitive Moat: Established customer and distributor relationships, research capabilities, product registrations and intellectual property provide advantages, though they do not prevent competition or earnings volatility.

Recent Developments

The supplied recent headlines include two investor-alert announcements from Pomerantz LLP, dated November 10 and November 12, stating that the firm is investigating claims on behalf of FMC investors. These are reports of an investigation, not a finding of wrongdoing or a determination of liability. The provided material does not specify the underlying allegations, so the matter’s scope and potential financial impact remain unclear. A separate article about record-high dividend yields mentions FMC in a broader discussion; it is not evidence that FMC has announced a dividend reduction.

Financial Snapshot

Market Cap$0.65B
P/E Ratio-0.16
52-Week Range$4.37 - $18.29
Dividend Yield6.14%
EPS (TTM)-$32.00
ROE-308.88%

Revenue & Earnings Trends

The supplied market-data excerpt reports revenue of approximately $2.815 billion and revenue growth of -80.50%, alongside a net loss of about $4.177 billion and a trailing EPS of -$32.83. The company profile data list EPS (TTM) at -$32.00 and ROE at -308.88%. These figures point to severe reported losses, but vendor datasets differ and the excerpt does not explain the accounting items behind the net loss or the unusually steep revenue-growth figure. The figures should be checked against FMC’s filings before being used in a detailed financial model.

For the quarter reported on October 29, 2026, EPS was -$4.41 against an estimate of $0.06509, a pronounced miss. A single quarter does not determine the company’s long-term prospects, but the size of this gap makes the next earnings release and management’s explanation especially important.

Balance Sheet Highlights

The data excerpt lists cash of approximately $735.8 million, total debt of $4.296 billion, a current ratio of 1.66 and a quick ratio of 0.89. Debt is substantial relative to the supplied $0.65 billion market capitalization, and the quick ratio indicates that readily available assets may not fully cover current liabilities. The excerpt also reports EBITDA of -$275.3 million, while free cash flow is listed as positive $728.1 million and operating cash flow as $351.3 million. Because these measures appear difficult to reconcile, they should be treated cautiously until confirmed against the company’s statements.

Valuation Analysis

Current Valuation Metrics

Forward P/E5.51Industry comparison unavailable
PEG RatioN/MNegative earnings make this unreliable
EV/EBITDAN/MReported EBITDA is negative
P/S Ratio~0.23Based on supplied market cap and revenue

Historical Comparison

A conventional comparison with FMC’s five-year average valuation is not reliable from the information provided, particularly because current earnings and book value are negative. The market-data excerpt gives a two-year average closing price of $25.24, compared with $5.21 on November 13, but share-price comparisons alone do not account for changes in earnings, capital structure or share count. The supplied price history also shows a 61.66% year-to-date decline and an 89.84% two-year total-return decline.

Fair Value Estimate

A dependable standalone fair-value estimate cannot be established from the supplied figures. A price-to-earnings or EV/EBITDA model is not meaningful with negative trailing earnings and EBITDA, while a discounted cash-flow analysis would require verified forecasts for normalized cash flow, debt repayment, capital spending and the dividend. Analyst targets in the supplied information range from $4 to $21, with a mean of $10.86; a separate Yahoo Finance excerpt gives a mean of $7.65 and median of $7.00. That gap is material, so target-based implied upside should not be treated as a single reliable valuation conclusion.

Competitive Landscape

Market Position

Market Share: Not established by the supplied data | Ranking: Established global crop-protection supplier, precise industry rank not verified

Key Competitors

$BAYRYBayer competes across crop protection, seeds and agricultural technologies.
Corteva (CTVA)Corteva supplies crop-protection products, seeds and related services.
$BASFYBASF is a large diversified chemical company with an agricultural solutions business.

Competitive Advantages

  • Research and Product Development: Agricultural chemistry and biological research can support differentiated products and new product launches.
  • Registrations and Intellectual Property: Regulatory approvals and protected product formulations can take time to replicate, although registrations can also be costly to maintain.
  • Distribution Relationships: Existing grower, retailer and distributor relationships provide routes to market across agricultural regions.

FMC competes with companies that may have broader portfolios, larger research budgets or greater geographic scale. Its ability to protect margins depends on product differentiation, customer demand and disciplined costs.

Earnings Track Record

Last 4 Quarters: 0 confirmed beats in supplied data / 1 confirmed miss; results for three quarters were not supplied

Recent Earnings History

Q3 2026-$4.41 vs $0.06509 estMISS
Q2 2026Not providedUNKNOWN
Q1 2026Not providedUNKNOWN
Q4 2025Not providedUNKNOWN

Guidance Trend

The supplied material does not include management’s full-year guidance or a sequence of revisions, so a reliable direction of travel cannot be assessed. The next listed report is expected February 3, 2027, with estimated EPS of $0.577. That estimate is a forecast, not a company commitment; the prior quarter’s large miss makes guidance assumptions, cash flow and balance-sheet commentary important items to review.

Analyst Sentiment

Consensus Rating: Hold

Strong Buy: 0Buy: 3Hold: 12Sell: 1Strong Sell: 1

Price Targets

  • Low: $4
  • Mean: $10.86 (+108.4% implied upside from $5.21)
  • High: $21

Recent Analyst Actions

The supplied recommendation breakdown totals 17 analysts and is unchanged from one month earlier, with 12 Holds and three Buys. A separate data excerpt lists 15 opinions and a mean target of $7.65, compared with the supplied $10.86 mean. The differing analyst counts and target averages may reflect different dates or coverage sets. The broad spread between the $4 low and $21 high also signals uncertainty, not a guaranteed outcome.

Recent News & Catalysts

Key Developments

  • Investor investigation announcements: Pomerantz LLP said on November 10 and November 12 that it is investigating claims on behalf of FMC investors. The announcements do not establish that claims are valid, and the provided summaries omit details of the allegations.
  • High dividend yield discussion: A November 13 article discussed record-high yields among several companies, including a general warning that unusually high yields can precede payout pressure. The supplied summary does not confirm a change to FMC’s dividend.
  • Sharp share-price decline: The market-data excerpt reports a 61.66% year-to-date loss and a 60.79% one-year total-return decline as of November 13. The decline raises questions about market expectations, earnings recovery and investor confidence.

Upcoming Catalysts

Next Earnings: February 3, 2027, expected | Key Events: Quarterly results, updated guidance, cash flow and debt disclosures, dividend coverage, and developments in the reported investor investigation

Technical Outlook

Current Price: $5.21 as of Friday, November 13 vs 52-Week High: $18.29 (-71.5% from high)

Trend Analysis

FMC’s supplied performance data show a steep downtrend, with losses across the five-day, one-month, three-month, six-month and year-to-date periods. The Friday close was near the supplied 52-week low of $4.37, although another data excerpt lists a low of $4.47. A one-day gain from $5.06 does not by itself establish a trend reversal, particularly after the reported long-term decline.

Key Levels

  • Resistance: $5.26, the supplied Friday range high; $7.00, the separate analyst median target and a potential reference level, not a technical signal
  • Support: $4.37, the supplied 52-week low; $4.00, the low analyst target, not a verified chart support level

The available price history is insufficient to confirm moving averages, volume-based support or momentum indicators. These levels are reference points from the supplied data rather than forecasts.

Bull vs Bear Case

Bull Case

  • Analyst Target Gap: The supplied $10.86 mean target is well above the Friday close, though another source reports a lower mean and estimates are not guarantees.
  • Potential Operating Stabilization: A recovery in agricultural demand, product mix or cost control could improve results if FMC can execute and normalize earnings.
  • Established Business: Research, product registrations and distribution relationships provide a platform for competing in crop protection.

Bull Scenario Reference: $10.86, the supplied analyst mean target, not an independent valuation

Bear Case

  • Losses and Earnings Miss: Negative trailing EPS, negative reported EBITDA and the Q3 2026 miss point to substantial operating and reporting uncertainty.
  • Debt and Payout Exposure: Reported debt of about $4.3 billion and a 6.14% indicated yield raise questions about financial flexibility and dividend coverage.
  • Continuing Downtrend: The share price is far below its 52-week high, and the market-data excerpt shows steep losses over multiple periods.

Bear Scenario Reference: $4.00, the supplied low analyst target, not a forecast

Risks to Consider

  • Valuation Risk: Negative earnings and EBITDA make common valuation multiples unreliable. The divergence in analyst target averages adds uncertainty to target-based comparisons.
  • Competitive Risk: FMC faces large agricultural and chemical competitors, while generic alternatives, product pricing and customer choices can pressure margins.
  • Macro Risk: Crop prices, weather, planting decisions, interest rates, currency movements and distributor inventories can affect demand and payment patterns.
  • Execution Risk: Management must address the earnings decline, maintain product development and manage debt. The reported investor investigation is an additional uncertainty, though the supplied notices do not establish wrongdoing.
  • Dividend Risk: A 6.14% yield can reflect a falling share price rather than a secure payout. The supplied information does not include a payout ratio or a confirmed dividend change, so coverage requires verification.
  • Data Quality Risk: Supplied sources disagree on price performance, 52-week low, analyst counts and target averages. Cash-flow and earnings figures also require reconciliation against regulatory filings.

Bottom Line

Investment Verdict: BEARISH

FMC’s situation combines a deeply reduced share price and potentially meaningful recovery scenarios with material evidence of financial stress, including a large reported quarterly loss, substantial debt and weak multi-period returns. The analyst consensus is Hold, but the wide target range and conflicting data make the headline implied upside a poor substitute for verified earnings and cash-flow analysis. This report is informational market analysis, not investment advice.

Action Items for Investors

  • Long-term investors: Track reported crop-protection demand, normalized earnings, debt reduction and dividend coverage before drawing conclusions about the durability of a recovery scenario.
  • Short-term traders: Treat the Friday gain and analyst targets as reference data rather than confirmation of a trend change; price volatility and data discrepancies remain significant.
  • Risk management: Review position sizing and exposure to agricultural inputs, debt and dividend risk in the context of your own circumstances. This is a general analytical consideration, not a personal recommendation.

What to Watch This Week

  • FMC’s price action and volume when US markets reopen Monday, November 16, relative to the $4.37 supplied 52-week low and the Friday range.
  • Any further details or company statements relating to the investor investigation announcements.
  • Verification of FMC’s latest financial statements, particularly debt, operating cash flow, free cash flow and dividend coverage.

Share this report

Share this article

Spread the word on social media

Think FMC will outperform? Prove it.

Free practice contests — earn Alpha Coins
Enter a Contest

Disclaimer: StockAlpha.ai content is for informational and educational purposes only. It is not personalized investment advice. Sentiment ratings and market analysis reflect data-driven observations, not buy, sell, or hold recommendations. Always consult a qualified financial advisor before making investment decisions. Past performance does not guarantee future results.

Spotted something wrong? Report an error.